It has been suggested that the anabolic effect of the parathyroid hormone (PTH), an FDA approved osteo-anabolic drug commonly used for osteoporosis treatment, requires Sfrp1 downregulation to stimulate Wnt signaling and osteoblastogenesis [41]. Here, SFRP1 is linked to osteoporosis.